Luis A. Carvajal, Ph.D.
Affiliations: | 2012 | Cancer Biology | Mount Sinai School of Medicine, New York, NY |
Area:
Molecular Biology, Genetics, OncologyGoogle:
"Luis Carvajal"Parents
Sign in to add mentor| James J. Manfredi | grad student | 2012 | Mount Sinai | |
| (Transcriptional Repression by the Tumor Suppressor p53.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Guerlavais V, Sawyer TK, Carvajal L, et al. (2023) Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development. Journal of Medicinal Chemistry |
| Zhou X, Singh M, Sanz Santos G, et al. (2021) Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discovery |
| Carvajal LA, Neriah DB, Senecal A, et al. (2018) Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine. 10 |
| Antony-Debré I, Paul A, Leite J, et al. (2017) Pharmacological inhibition of the transcription factor PU.1 in leukemia. The Journal of Clinical Investigation |
| Carvajal LA, Steidl U. (2016) Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. Cell Stem Cell. 19: 6-8 |
| Will B, Vogler TO, Narayanagari S, et al. (2015) Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nature Medicine |
| Lukin DJ, Carvajal LA, Liu WJ, et al. (2015) p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Molecular Cancer Research : McR. 13: 16-28 |
| Hamard PJ, Barthelery N, Hogstad B, et al. (2013) The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes & Development. 27: 1868-85 |
| Carvajal LA, Manfredi JJ. (2013) Another fork in the road--life or death decisions by the tumour suppressor p53. Embo Reports. 14: 414-21 |
| Carvajal LA, Hamard PJ, Tonnessen C, et al. (2012) E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes & Development. 26: 1533-45 |